KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.

Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog, Inger-Tove Jentoft van de Vooren, Lowan Han Stewart, Ingrid Autran, Mark Berthold-Losleben, Lynn Mørch-Johnsen, René Holst, Ingmar Clausen, Ole A Andreassen

Br J Psychiatry 227(5) 1-7

PMID40641116
PMCIDPMC12550655
DOI10.1192/bjp.2025.10320
发表日期2025-07-11
摘要

摘要

BACKGROUND: 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic stress disorder, but has not been investigated for a primary diagnosis of major depressive disorder (MDD). AIM: We aimed to explore the proof of principle and safety as a first study with MDMA-AT for MDD, and to provide preliminary efficacy data. METHOD: Twelve participants (7 women, 5 men) with moderate to severe MDD received MDMA in 2 open-label sessions 1 month apart, along with psychotherapy before, during and after the MDMA sessions, between January 2023 and May 2024. The primary outcome measure was mean change in Montgomery-Asberg Depression Rating Scale (MADRS), and the secondary outcome measure was mean change in functional impairment as measured with the Sheehan Disability Scale (SDS), both from baseline to 8 weeks following the second MDMA session. We used descriptive statistics and the two-tailed Wilcoxon signed-rank test to compare baseline and outcome scores. Repeated measures were analysed by a mixed-effects model. RESULTS: Baseline MADRS was 29.6 (s.d. 4.9). Feasibility was demonstrated with sufficient recruitment and retention. MADRS scores were significantly reduced post treatment compared with baseline (mean difference -19.3, s.e. 2.4, CI -14.8 to -23.8, P < 0.001). SDS scores significantly decreased from baseline (mean difference -11.7, s.e. 2.2, CI -7.5 to -15.9, P = 0.001). There were no adverse events of special interest, and no unexpected or serious adverse events. CONCLUSION: The study met the primary objectives of safety and feasibility, and provided indications of efficacy for MDMA-AT for MDD. Further studies with a randomised design are required to confirm these findings. TRIAL REGISTRATION: EudraCT no. 2021-000805-26.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。